|
|
Article: CytRx licenses use of breakthrough target demonstrated to regulate obesity.(Imperial College Innovations Limited )
- Article from:
- BIOTECH Patent News
- Article date:
- June 1, 2004
CopyrightCOPYRIGHT 2004 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CytRx Corporation (Los Angeles, CA) has entered into a license agreement with Imperial College Innovations Limited (London, England), the technology transfer company of Imperial College London (London, England), for exclusive rights to Imperial's intellectual property covering a drug screening method using Rip140, a nuclear hormone co-repressor which regulates fat accumulation. This proprietary technology is covered by a pending patent application filed by the licensor. Imperial College Innovations will receive a license fee, milestone payments, and royalties on net sales of any resulting products.
In experiments conducted by Professor Malcolm G. Parker, Ph.D., ...
Related newspaper, magazine, and journal articles:
|
|
Article: Research from Imperial College London, ...
Heart Disease Weekly;
December 21, 2008 ;
700+ words
... ... wrote U. Siedlecka and colleagues, Imperial College London, Imperial College (see also Cardiology). The researchers ... National Heart & Lung Institute, Imperial College, London, UK. The publisher's contact information ...
|
|